Selected article for: "critical illness and SAPS II score"

Author: Chavarria, Adrián Palacios; Vázquez, Rafael Ricardo Valdez; Cherit, José Guillermo Domínguez; Bello, Héctor Herrera; Suastegui, Humberto Castillejos; Moreno-Castañeda, Lidia; Alanís Estrada, Gabriela; Hernández, Fabián; González-Marcos, Omar; Saucedo-Orozco, Huitzilihuitl; Pech, Linaloe Manzano; Márquez, Ricardo; Guarner-Lans, Verónica; Torres, Israel Pérez; Soto, Maria Elena
Title: Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19
  • Cord-id: 618zgv4i
  • Document date: 2021_2_27
  • ID: 618zgv4i
    Snippet: The type 2 coronavirus causes severe acute respiratory syndrome (SARS-CoV-2) and produces pneumonia with pulmonary alveolar collapse. In some cases it also causes sepsis and septic shock. There is no specific treatment for coronavirus disease 2019 (COVID-19). Vitamin C (Vit C), Vitamin E (Vit E), N-acetylcysteine (NAC) and Melatonin (MT) increase the intracellular content of GSH, kidnap free radicals and protect DNA, proteins in the cytosol and lipids in cell membranes. Pentoxifylline (Px) has a
    Document: The type 2 coronavirus causes severe acute respiratory syndrome (SARS-CoV-2) and produces pneumonia with pulmonary alveolar collapse. In some cases it also causes sepsis and septic shock. There is no specific treatment for coronavirus disease 2019 (COVID-19). Vitamin C (Vit C), Vitamin E (Vit E), N-acetylcysteine (NAC) and Melatonin (MT) increase the intracellular content of GSH, kidnap free radicals and protect DNA, proteins in the cytosol and lipids in cell membranes. Pentoxifylline (Px) has anti-inflammatory activities. Here we evaluate the effect of Vit C, Vit E, NAC, and MT plus Px in COVID-19 patients with moderate and severe pneumonia. 110 patients of either sex were included. They were divided into five groups with 22 patients each. Group 1 received Vit C+Px, group 2 Vit E+Px, group 3 NAC+Px, group 4 MT+Px, and group 5 only Px. Oxidative stress (OS) markers such as lipid peroxidation (LPO) levels, total antioxidant capacity (TAC) and nitrites (NO(2)(-)) were evaluated in plasma. The antioxidant therapy improved the survival scores including the Sequential Organ Failure Assessment (SOFA), the Acute Physiology and chronic Health Evaluation II (Apache II), the Simplified Acute Physiology Score II (SAPS II), the Critical Illness Risk Score, Launched during COVID-19 crisis (COVIDGRAM) and the Glasgow Coma Scale (GCS). We found that LPO was elevated (p≤0.04) and TAC (p≤0.03), NO(2)(-) (p≤0.04) and inflammation markers such as interleukin-6 (IL-6, p≤0.01) C reactive protein (CRP, p≤0.01) and procalcitonin (PCT, p≤0.05) were diminished in COVID-19 patients upon admission to the hospital. The different antioxidants reversed this alteration at the end of the treatment. The treatment with antioxidant supplements such as Vit C, E, NAC, and MT plus Px could decelerate the aggressive and lethal development of COVID-19. Antioxidant therapy can be effective in this pandemia since it improves the survival scores including SOFA, Apache II, SAPS II, COVIDGRAM, GCS by lowering the LPO, IL-6, CRP, PCT and increasing systemic TAC and NO(2)(-).

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute ali lung injury: 1, 2, 3
    • absence presence and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absence presence and acute increase: 1
    • absence presence and acute lung injury: 1, 2, 3
    • absence presence and acute myocardial infarction: 1, 2
    • absence presence and acute phase: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and adhesion molecule: 1, 2, 3, 4
    • active recent and acute ali lung injury: 1
    • active recent and acute ards respiratory distress syndrome: 1, 2
    • active recent and acute lung injury: 1
    • active recent and acute myocardial infarction: 1
    • active recent and acute phase: 1
    • active recent and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active recent and adjuvant therapy: 1
    • active site and acute ards respiratory distress syndrome: 1, 2
    • active site and acute lung injury: 1, 2
    • active site and acute myocardial infarction: 1
    • active site and additive effect: 1